Regenerative Patch Technologies LLC (RPT) is a biotechnology company dedicated to developing innovative cell-based implant technologies aimed at treating retinal diseases, particularly focusing on age-related macular degeneration (AMD). Their flagship product, the California Project to Cure Blindness-Retinal Pigment Epithelium 1 (CPCB-RPE1), is a composite subretinal implant that features a polarized monolayer of human embryonic stem cell-derived retinal pigment epithelium (hESC-RPE) on an ultra-thin synthetic substrate designed to replicate Bruch's membrane. This implant is specifically designed to address the dysfunction and loss of RPE cells, which are critical for the health of photoreceptors in the retina. The CPCB-RPE1 implant is currently undergoing a Phase 2b clinical trial to evaluate its safety and efficacy in patients suffering from geographic atrophy, a severe form of AMD that leads to significant vision loss.

The development of the CPCB-RPE1 implant is supported by substantial funding from the California Institute for Regenerative Medicine (CIRM), which awarded RPT over $12 million for this clinical trial. The goal of the implant is to promote the survival and function of retinal cells, potentially halting disease progression and improving vision in affected patients. With geographic atrophy impacting millions globally and no approved therapies currently available to enhance vision in these patients, RPT's research represents a significant advancement in the field of regenerative medicine and offers hope for those suffering from this debilitating condition.

United States

Regenerative Patch Technologies LLC (RPT) is a CA-based biotechnology company focused on the development of stem cell-based therapies designed to reverse blindness caused by advanced dry age related macular degeneration (AMD).  

Regenerative Patch Technologies

Company Details